11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Abstract
The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee (https://doi.org/10.2337/dc22-SPPC), are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc22-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Transient increases in urine albumin excretion are reported with short-term hyperglycemia, exercise, urine tract infections, sustained blood pressure elevation, heart failure, fever, and hyperlipidemia (451).”
From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [451]
In the citing paper
“The ADA/ EASD statement recommends that patients with T2D who have established ASCVD, CKD, or clinical heart failure be treated with an SGLT2i (or GLP-1 RA) with proven cardiovascular bene fi t as part of a glucose-lowering regimen independent of HbA1c, but with consideration of patient-speci fi c factors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [145]
In the citing paper
“Both the ADA and KDIGO recommend annual screening of patients with diabetes for CKD (17,18) (Fig. 1).”
In the citing paper
“This recommendation is based on strong evidence that SGLT2i reduce CKD progression, HF, and ASCVD risk in patients with T2D and CKD.”
In the citing paper
“These trials enrolled participants with albuminuria (ACR ≥300 mg/g and ≥200 mg/g, respectively); therefore, current evidence is strongest in this population, as emphasized by ADA recommendations (17) (Table 1).”
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023 · cited 1×
“Intensive glycemic control with the goal of achieving near-normoglycemia has been shown in large prospective randomized studies to delay the onset and progression of albuminuria and reduced eGFR in patients with type 1 diabetes (50,51) and type 2 diabetes (1,52 – 57).”
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Cited by
Items 201–300 of 349
Jiang, J., Zhou, X., Lan, L., Weng, J., & Ren, W. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02119-7 · Cited by 6
Lin, Y., Wu, P., Guo, L., Feng, Q., Wang, L., Lin, X., Yang, C., Liu, N., Wen, C., Li, X., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01439-9 · Cited by 7
TYPE 2 DIABETES MELLITUS: EPIDEMIOLOGY, COMPLICATIONS AND EARLY DIAGNOSIS
Velychko, V. I., Yurchenko, I. V., Lahoda, D. O., & Yurchenko, Y. I. (2023) · doi:10.32782/2226-2008-2023-3-14 · Cited by 9
Cheng, Y., Liu, Y., Lin, L., Li, D., Peng, L., Zheng, K., Tao, J., & Li, M. (2024) · Renal Failure · doi:10.1080/0886022x.2023.2295425 · Cited by 6
“However, MRA-induced hyperkalaemia remains a major concern in patients with DKD presenting an eGFR 60 mL/min/1.73 m 2 [8,12].”
BackgroundInfluentialExploring diabesity pathophysiology through proteomic analysis using Caenorhabditis elegans
Malaimegu, S., Mir, D. A., Ankita, K., Sindunathy, M., Kishore, H. D., Ravichandiran, V., & Balamurugan, K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1383520 · Cited by 7
“Studies have elucidated that the metabolic dysregulation due to obesity results in lipotoxicity, cytotoxicity, and adipocyte stress which contribute to the development of diabesity (9).”
Moriconi, D., Nannipieri, M., Jadoon, M., Solini, A., & Bruno, R. M. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70064 · Cited by 7
Wright, W. L., Urquhart, S., & Brunton, S. (2023) · Journal of Primary Care & Community Health · doi:10.1177/21501319231153599 · Cited by 7
Tong, P. C.-Y., Chan, S. C.-P., Chan, W. B., Ho, K. K. L., Leung, G. T.-C., Lo, S. H.-K., Mak, G. Y. K., & Tse, T.-S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103403 · Cited by 8
Ebert, T., Sattar, N., Greig, M., Lamina, C., Froissart, M., Eckardt, K., Floege, J., Kronenberg, F., Stenvinkel, P., Wheeler, D. C., et al. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.05.010 · Cited by 6
Du, Y., Gui, C., Gu, L., Chen, Y., & Liu, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1237583 · Cited by 6
Sammut‐Powell, C., Sisk, R., Budd, J., Patel, N., Edge, M. D., & Cameron, R. S. (2022) · Future Healthcare Journal · doi:10.7861/fhj.2022-0020 · Cited by 6
Song, R., Hu, W., Cheng, R., Zhao, Y., Qin, W., Li, X., Zhu, Y., Gan, L., & Liu, J. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad172 · Cited by 6
Precision Medicine and/or Biomarker Based Therapy in T2DM: Ready for Prime Time?
Rossing, P. R., Frimodt‐Møller, M., & Persson, F. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151430 · Cited by 5
Pestka, D. L., Murphy, D. P., Huynh, P., Rechtzigel, J. A., Kjos, S., Ellich, L. M., Kaplan, A. N., Taylor, B. C., Atwood, M., Polsfuss, B. A., et al. (2024) · BMC Nephrology · doi:10.1186/s12882-023-03446-1 · Cited by 5
“…has been produced on the benefits of SGLT2i, the American Diabetes Association (ADA) and the Kidney Disease Improving Global Outcomes (KDIGO) guidelines now recommend that SGLT2i be given to all patients with mild to moderate CKD and type 2 diabetes regardless of their glycemic control [12, 13].”
BackgroundResearch progress on small extracellular vesicles in diabetic nephropathy
Yu, B., Wang, L., Mao, Y., Hu, X., Lu, Y., He, J., Yuan, X., Zhang, M., & Chen, Z. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1535249 · Cited by 5
Weltman, M. R., Han, Z., Lavenburg, L.-M. U., Alghwiri, A. A., Yabes, J. G., Nolin, T. D., & Jhamb, M. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.100995 · Cited by 5
Wang, Y., Liu, Y., Gu, W., Cai, B., Lei, M., Luo, Y., & Zhang, N. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1532682 · Cited by 6
Deethai, P., Siriwathanakul, C., Pitchakarn, P., Imsumran, A., Wongnoppavich, A., Dissook, S., & Chewonarin, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178176 · Cited by 6
“The primary causes of type 2 diabetes are insulin resistance, defined by reduced cellular response to insulin, and auto-lipolysis in adipose tissue leading to elevated levels of blood glucose and free fatty acids (FFAs) [4].”
Yu, D., Wang, Z., Cai, Y., Osuagwu, U. L., Pickering, K., Baker, J., Cutfield, R. G., Orr‐Walker, B., Sundborn, G., Jayanatha, K., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003077 · Cited by 6
“The CEM algorithm that is a monotonic imbalance reducing matching method, which indicates the balance between comparison groups is chosen by ex-ante user choice, rather than identified through the common laborious process of ‘checking after the fact, tweaking the method, and repeatedly…”
Nasser, S. A., Arora, N., & Ferdinand, K. C. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2312411 · Cited by 5
“Worldwide, the number one cause of death is CVD which often coincides with diabetes, diabetic kidney disease (DKD) and other forms of chronic kidney disease (CKD), with CVD coupled to the development of DKD [2].”
BackgroundYokoyama, Y., Hanai, K., Mori, T., Yamamoto, Y., Yoshida, N., Murata, H., Shinozaki, T., & Babazono, T. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02328-y · Cited by 5
Scamporrino, A., Mauro, S. D., Filippello, A., Marco, G. D., Pino, A. D., Scicali, R., Marco, M. D., Martorana, E., Malaguarnera, R., Purrello, F., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119412 · Cited by 5
Wu, M., Teng, T. K., Tsang, C. T., Chan, Y., Lee, C., Ren, Q. W., Huang, J., Cheang, I., Tse, Y.-K., Li, X., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad081 · Cited by 7
Hypoglycemia in Type 1 Diabetes Mellitus
Şakar, K., & Çınar, N. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1004108 · Cited by 9
ADA Standards of Medical Care in Diabetes 2022 - what's new?
Škrha, J. (2022) · Vnitřní lékařství · doi:10.36290/vnl.2022.017 · Cited by 11
Deravi, N., Sharifi, Y., Koohi, F., Zadeh, S. S. T., Masrouri, S., Azizi, F., & Hadaegh, F. (2023) · BMC Public Health · doi:10.1186/s12889-023-15463-8 · Cited by 6
Shestakova, M. V., Dobronravov, V., As, A., Antsiferov, M. B., Batyushin, М. М., Bobkova, I. N., Galstyan, G. R., Demidova, T. Y., Klimontov, V. V., Mkrtumyan, A. M., et al. (2023) · Diabetes Mellitus · doi:10.14341/dm13020 · Cited by 5
Construction of a Nomogram-Based Prediction Model for the Risk of Diabetic Kidney Disease in T2DM
Wang, X., Liu, X., Zhao, J., Chen, M., & Wang, L. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s442925 · Cited by 5
Pinheiro, A. H. G., Pereira, B. D. O., Silva, L. S. D., de Melo, F. T. C., de Souza, A. C. C. B., Leal, V. S. G., de Figueiredo, P. B. B., Neto, J. F. A., dos Santos, M. C., de Queiroz, N. N. M., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115663 · Cited by 5
“This complication significantly impacts 20 to 40% of patients diagnosed with Diabetes Mellitus (DM) [8].”
BackgroundNadendla, R. R., Khairunnisa, K., Aziz, N., Pyne, C., Panigrahy, U. P., Wal, P., Kulkarni, M. H., & Rasheed, A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998291920240611063402 · Cited by 4
Antsiferov, M. B., Kotenko, O. N. K., Kobalava, Z. D., Demidova, T. Y., Маркова, Т. Н., Tolkacheva, V. V., Morgunov, L. Y., Андреева, А. В., Pashkova, E. Y., Khaziakhmetova, M. R., et al. (2024) · Diabetes Mellitus · doi:10.14341/dm13146 · Cited by 4
Siebenhofer, A., Loder, C., Avian, A., Platzer, E., Zipp, C., Mauric, A., Spary-Kainz, U., Berghold, A., & Rosenkranz, A. R. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1412689 · Cited by 4
Nesti, L., Chiriacò, M., Sacchetta, L., Moriconi, D., Santoni, L., Pugliese, N. R., Gallo, S., Cimbalo, N., Forotti, G., Chiriacò, G., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae305 · Cited by 5
Zhao, H., Wang, Y., Liu, Y., Du, Z., & Tian, L. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70107 · Cited by 4
Chonko, K., Russo‐Alvarez, G., Isaacs, D. M., Wang, L., & Soric, A. (2023) · INNOVATIONS in pharmacy · doi:10.24926/iip.v14i2.5456 · Cited by 5
Frazer, M., Swift, C., Sargent, A., Leszko, M., Buysman, E. K., Gronroos, N. N., Alvarez, S., Dunn, T. J., Noone, J. M., & Gamble, C. L. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01341-y · Cited by 4
Raharinavalona, S. A., Raherison, R. E., Miandrisoa, R. M., Andrianasolo, R. L., & Rakotomalala, A. D. P. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s467316 · Cited by 5
“14,15 Retinopathy is posed in the face of abnormalities in the examination of the vitreous and fundus after pupillary dilation.”
BackgroundYu, J., Zhang, Z.-Y., Liu, S.-P., Long, H., Wang, T., Huang, F., Guo, J., Xu, W., & Li, F. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119129 · Cited by 4
Antwi‐Boasiako, C., Obeng, K. A., Amissah-Arthur, K. N., Musah, L., Abaidoo, B., Awuviri, H. W., Abbey, J. A., Awula, P., Tei, R. K., Agyemang, C. O., et al. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100139 · Cited by 4
Laue, K., Schultz, M., Talbot-Montgomery, E., Garrick, A., Java, A., Corbett, C., Lammert, D. M., Rogers, J., Davis, K., Malhotra, K., et al. (2024) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2023.12.004 · Cited by 4
Ars, J., Ribera, A., Udina, C., Maltese, G., Ortiz-Zúñiga, Á., Mota-Foix, M., Sarró, E., Castellano‐Tejedor, C., & Inzitari, M. (2024) · The Journal of Frailty & Aging · doi:10.14283/jfa.2024.33 · Cited by 4
“Comorbidities and T2DMC were defined as present based on the information contained in the health records and according to the clinical criteria of the American Diabetes Association (ADA) (22, 23).”
Geraci, G., Sinatra, N., Paternò, V., Calabrese, V., Cassataro, G., Cuttone, G., Geraci, C., Esposito, R., Mancusi, C., Pucci, G., et al. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07890-7 · Cited by 3
Ingle, M., Khatib, R., Du, Y., Valuckaite, V., Singh, R., Kong, S. X., Williamson, T. E., & Baman, S. (2024) · International Summit on Diabetes, Endocrinology and Metabolic Disorders · doi:10.1136/bmjph-2023-000679 · Cited by 3
Kidney fat by magnetic resonance spectroscopy in type 2 diabetes with chronic kidney disease
Heinrich, N. S., Pedersen, R. P., Vestergaard, M. B., Lindberg, U., Andersen, U. B., Haddock, B., Fornoni, A., Larsson, H. B. W., Rossing, P. R., & Hansen, T. W. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108923 · Cited by 3
The Diagnostic Performance of a Clinical Diagnosis of Diabetic Kidney Disease
Tan, K., McDonald, S. P., & Hoy, W. E. (2023) · Life · doi:10.3390/life13071492 · Cited by 3
[Non-Classical Clinical Types and Pathological Changes of Diabetic Kidney Disease: A Review].
Fang, C., Sun, L., Liu, Y., Xiao, L., & Sun, L. (2023) · 四川大学学报:医学版 · doi:10.12182/20231160102 · Cited by 3
Verifying The Association Between IL6 -174G/C Polymorphism in Type 2 Diabetes Mellitus
Al-azzawi, N. N., Hussein, M. K., & .Khalaf, M. I. (2024) · Journal Port Science Research · doi:10.36371/port.2024.1.6 · Cited by 6
Clements, J. N. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001248 · Cited by 3
Pulicharam, J., Davidson, J., Bubb, C., Evans, S. W., & Davidson, M. B. (2022) · Medical Research Archives · doi:10.18103/mra.v10i12.3396 · Cited by 4
Kanumilli, N., Butler, J., Makrilakis, K., Rydén, L., Vallis, M., Wanner, C., Zieroth, S. R., Alhussein, A., & CHENG, A. Y. Y. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01418-0 · Cited by 5
Ma, Q., Song, S., & Xu, G. (2023) · Acta Clinica Belgica · doi:10.1080/17843286.2023.2222243 · Cited by 3
Khamseh, M. E., Malek, M., Hashemi‐Madani, N., Ghassemi, F., Rahimian, N., Ziaee, A., Foroughi‐Gilvaee, M. R., Faranoush, P., Sadighnia, N., Elahinia, A., et al. (2023) · Iranian Journal of Blood and Cancer · doi:10.61186/ijbc.15.4.293 · Cited by 8
Liu, M., Di, Y. M., Zhang, L., Yang, L., La, Z., Chen, J., Wang, R., Xie, X., Lan, F., Xie, L., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1334609 · Cited by 3
Greene, S. J., Böhm, M., Bozkurt, B., Butler, J., Cleland, J. G. F., Coats, A. J. S., Desai, N. R., Grobbee, D. E., Kelepouris, E., Pinto, F. J., et al. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.08.048 · Cited by 3
“2,3,13 Furthermore, HF guidelines provide recommendations for the management of chronic HK, including consideration of the use of potassium (K + ) binders as a potential strategy, which may allow for safer initiation, and continued use or up-titration of RAASis in a larger proportion of patients.”
Yu, J., Tu, X., Xu, K., Tang, X., Wu, Y., & Jiang, X. X. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1481977 · Cited by 3
Garofolo, M., Penno, G., Solini, A., Orsi, E., Vitale, M., Resi, V., Bonora, E., Fondelli, C., Trevisan, R., Vedovato, M., et al. (2025) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70061 · Cited by 2
Yang, Q., Qin, C., Lang, Y., Yang, W., Yang, F., Yang, J., Liu, K., Yuan, J., Zou, Y., & Liu, F. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s531413 · Cited by 4
“…transporter 2 inhibitors (SGLT-2Is), as the first-line therapeutic agent, are recommended by major guidelines in T2DM concurrent CKD. 1,11 To achieve personal glycemic goal or gain additional kidney and heart protection, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are also…”
Pecoits‐Filho, R., Kanda, E., Kashihara, N., Ofori‐Asenso, R., Chen, H., Pentakota, S., Järbrink, K., Sánchez, J. J. G., Lam, C. S. P., Fishbane, S. N., et al. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf175 · Cited by 3
Raharinavalona, S. A., Randriamanana, M. A., Ratsimbazafy, S. J. N., Raharisoa, F. R., & Rakotomalala, A. D. P. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04435-2 · Cited by 2
Katsanou, P., & Marakomichelakis, G. (2026) · Springer eBooks · doi:10.1007/978-3-031-82232-2_39 · Cited by 2
Milluzzo, A., Maugeri, A., Barchitta, M., Lio, R. M. S., Rocca, D., Marino, A., Frittitta, L., Sciacca, L., & Agodi, A. (2026) · Nutrients · doi:10.3390/nu18121970 · Cited by 3
“Estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation [38].”
Principais fatores de risco para mortalidade de longo prazo em pacientes com úlceras de pé diabético
Gomes, G. V. A., da Silva, D. R. P., Lima, C. M. E., Madeira, J. F., Carvalho, B. M. M., Vanderley, A. M., & do Nascimento, J. W. A. (2023) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e12620.2023 · Cited by 2
Yamaguchi, S., Shimabukuro, M., Tanaka, A., Imai, T., Hiramitsu, S., Takahashi, N., Kadokami, T., Ajioka, M., Suzuki, M., Node, K., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14876 · Cited by 2
Finerenone in SGLT-2 Inhibitors Era: Current Positioning in Diabetic Kidney Disease
Singh, A. K., Singh, R., Shah, V. N., & Misra, A. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0041 · Cited by 2
Lee, S. E., Yoo, J., Choi, H. S., Han, K., & Kim, K. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2022.0096 · Cited by 3
“Our study results support the American Diabetes Association recommendations for the annual screening of asymptomatic adults for eGFR and UACR [5], especially for risk stratification of HHF.”
InfluentialPicow, E. (2023) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000000921 · Cited by 2
Hypertension and Chronic Kidney Disease Including Dialysis
Dhaybi, O. A., & Bakris, G. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00035-9 · Cited by 2
Rethinking the Impact and Management of Diabetes in Heart Failure Patients
Schütt, K. S. (2023) · Current Heart Failure Reports · doi:10.1007/s11897-023-00633-x · Cited by 5
“Thus, it is of utmost important to screen all patients with diabetes for the presence of CKD. Routine annual screening for CKD is recommended for all adults living with diabetes with spot urine sample UACR testing as well as serum creatinine testing to determine GFR [51, 52].”
BackgroundSaito, H., Tanabe, H., Hirai, H., Higa, M., Tanaka, K., Yamaguchi, S., Maimaituxun, G., Masuzaki, H., Kazama, J. J., & Shimabukuro, M. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14272 · Cited by 2
“The covariates used for the Cox proportional hazards model were chosen from possible confounding factors for DKD 9,14 – 17 .”
InfluentialMarx, N., CHENG, A. Y. Y., Agarwal, R., Greene, S. J., & Abu-Hantash, H. (2022) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suac114 · Cited by 3
Nolasco-Rosales, G. A., Villar-Juárez, G. E., Pérez-Osorio, D. A., Cruz-Castillo, J. D., Molina-Guzman, G., González‐Castro, T. B., Tovilla‐Zárate, C. A., Rodríguez-Sánchez, E., Mendoza, A. D. G., Hernández-Palacios, F., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.04.007 · Cited by 2
Duan, S., Lu, F., Sun, R., Chen, C., Chen, S., Geng, L., Qian, L., Pan, Y., Zhang, C., Zeng, M., et al. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103037 · Cited by 2
Lou, X., Yang, Z. H., Wu, K., Li, W., Hu, W., Nie, R., Tu, P., & Duan, P. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s390483 · Cited by 2
“However, many previous studies have found that OPG levels in type 2 diabetic patients with albuminuria were significantly higher than those in patients without albuminuria.8,11,14 High levels of OPG also seemed to have a greater risk of developing to stage 3–5 CKD or ESRD.15 These results are somewhat different from o…”
BackgroundInfluentialМетаболічні ефекти інгібіторів натрійзалежного котранспортера глюкози 2 типу
Кедик, А. В., & Kutsin, O. O. (2022) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2022-4-42 · Cited by 2
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 2
The role of finerenone in the management of CKD in T2D –Practical considerations for primary care
Kanumilli, N., Miszon, M., Schnell, O., & Groop, P. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.09.001 · Cited by 3
Costa, E. F. D., Ferreira, A. M. C., Mazzali, M., Lourenço, G. J., & Lima, C. S. P. (2025) · Head & Neck · doi:10.1002/hed.28179 · Cited by 1
“Based on established criteria, patients were categorized as smokers [25], drinkers [25], hypertensive [26], and diabetic [27].”
Ortíz, A., Cebrián, A., Soto, A., Reyes, A., & Górriz, J. L. (2025) · Nefrología · doi:10.1016/j.nefro.2025.501338 · Cited by 1
Amiri, A., Entezari, F. J., Chahkand, M. S. G., Jannat, B., & Seighali, N. (2026) · BMC Nutrition · doi:10.1186/s40795-026-01424-y · Cited by 1
Pollock, C. A., Sánchez, J. J. G., Carrero, J. J., Kumar, S. R., Pecoits‐Filho, R., Lam, C. S. P., Chen, H., Kanda, E., Lainščak, M., & Wheeler, D. C. (2023) · Diabetic Medicine · doi:10.1111/dme.15200 · Cited by 1
“9,15 By contrast, there are no restrictions on insulin use in individuals with renal impairment— doses can be uptitrated to achieve glycaemic goals 20,25 — and some individuals in the analytic cohort may have had late-stage T2D and required insulin due to beta-cell failure.”
BackgroundMethodCribado y diagnóstico de la enfermedad renal crónica en personas con diabetes mellitus
Mundet, X. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.renal.art5 · Cited by 1
Prevención de la enfermedad renal crónica en personas con diabetes mellitus
Simarro, F. L. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.renal.art6 · Cited by 3
“El bloqueo de sistema renina-angio-tensina-aldosterona (SRAA) con IECA o ARA II sería la opción preferida para el tratamiento de la PA si FG 60 ml/min/1,73 m 2 y excreción urinaria de albúmina ≥ 300 mg/g de creatinina debido a los beneficios demostrados para prevenir la progresión de la ERC 2,13 .”
Inpatient Management of Patients with Diabetes and Kidney Disease
Patel, E., Kim, S. H., & Gianchandani, R. Y. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_23 · Cited by 2
A Center for Nutrition Care to Provide Renal Nutrition Therapy to Chronic Kidney Disease Patients
Gutiérrez, A., Nava-Hernández, J., Arronte, R. U., Gamiño, A. A., Salinas-Rico, A., Aldana-Solís, N., Rosa-Diez, S. D. L., Cárdenas, R. M., & Kopple, J. D. (2025) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2025.02.005 · Cited by 1
Chronic kidney disease and vascular risk - what's new?
Santamaría, R., de Mier, M. V. P.-R., & Haad, C. R. (2022) · Hipertensión y Riesgo Vascular · doi:10.1016/j.hipert.2022.01.001 · Cited by 1
Diabetes: how to manage chronic kidney disease
Clements, J. N. (2022) · Drugs in Context · doi:10.7573/dic.2021-9-10 · Cited by 1
Cardiorenal effects of SGLT2 inhibitors: who might benefit?
Klug, E., Rayner, B. L., Wasserfall, M., Kok, A., Mpe, M., Ruder, S., Mohamed, N., & Webb, D. (2023) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/16089677.2023.2275898 · Cited by 1
“59 Precautions when prescribing SGLT2 inhibitors to patients with type 2 diabetes Adverse events with SGLT2 inhibitors are uncommon.”
BackgroundZhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1623050/v2 · Cited by 1
Finerenone: Do We Really Need an Additional Therapy in Type 2 Diabetes Mellitus and Kidney Disease?
Manoharan, D., Gangoo, N., & Hinchliffe, W. (2025) · British Journal of Hospital Medicine · doi:10.12968/hmed.2024.0715 · Cited by 1
Clinical practice guidelines update 2022: Focus on diabetes
Cornell, S. A. (2022) · Pharmacy Today · doi:10.1016/j.ptdy.2022.05.022
Clinical evidence of traditional Chinese medicine: From opportunity to challenge
Liang, B., & Gu, N. (2022) · Phytomedicine Plus · doi:10.1016/j.phyplu.2022.100329
Part Six: Antidiabetic Medication Benefits Beyond Glucose Lowering in Older People
Pogge, E. K., & Early, N. K. (2022) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2022.477
Nicholas, S. B., & Mottl, A. K. (2022) · Nephrology Self-Assessment Program · doi:10.1681/nsap.00142022
Új terápiás stratégiák a diabéteszes vesebetegség kezelésében
Balogh, Z. (2022) · Diabetologia Hungarica · doi:10.24121/dh.2022.25
Update on Medical Management of Diabetes
Katwal, D., JAMES, D. J., & Dagogo-Jack, S. E. (2023) · Orthopedic Clinics of North America · doi:10.1016/j.ocl.2023.02.005
Tunca, O. (2023) · JOJ Urology & Nephrology · doi:10.19080/jojun.2023.07.555726
Crannage, E. F., Nguyen, K. L., Ellebrecht, M. D., Challen, L., & Crannage, A. J. (2023) · Journal of Pharmacy Technology · doi:10.1177/87551225231169620 · Cited by 1
Sun, Y., Zhang, Z., Sun, W., Jin, D., An, X., Zhang, Y., Yang, C., Zhang, Y., Duan, Y., Kang, X., et al. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4455400
Managing Stable Coronary Artery Disease in Diabetes
Koulouridis, I., & Johnstone, M. T. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_23
Diabetic Kidney Disease and COVID-19
Abate, M. T., Maturostrakul, B. N., & Nair, V. V. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-28536-3_5
Metadata
- Authors
- American Diabetes Association Professional Practice Committee
- Corresponding author
- American Diabetes Association Professional Practice Committee
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-12-16
- Volume
- 45
- Issue
- Supplement_1
- Pages
- S175-S184
- ISSN
- 0149-5992 (ISSN-L)
- OpenAlex
- W4200340161
- Semantic Scholar
- 40f2cfa2d0038ac9f80bb94b8f8217ad1566bd6e
- Cited by
- 344
- References
- 112
- Citations by year
- 2026: 15 · 2025: 38 · 2024: 66 · 2023: 123 · 2022: 101 · 2021: 1
- FWCI
- 11.91
- Type
- journal article
- Language
- en
- Update notices
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- chronic kidney disease, diabetes mellitus, risk management, clinical guidelines, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Renal Insufficiency, Chronic, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.